Clinical trial · Observational
TAD After Chemotherapy in Locally Advanced Breast Cancer
Target Axillary Dissection After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
NCT05763641CI-TRIAL-00094895recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Locally Advanced | — | UNRESOLVED | — |
| Sentinel Lymph Node | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Target Axillary Dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- TAD validation in locally advanced breast cancer
- timeFrame
- 3 years
- description
- False negative rate when performing TAD after NAC
Secondary outcomes (2)
- measure
- Ultrasound validity to evaluate axillary response after NAC
- timeFrame
- 3 years
- description
- False-negative and positive rates of axillary ultrasound after NAC to assess lymph node response
- measure
- MRI validity to evaluate axillary response after NAC
- timeFrame
- 3 years
- description
- False-negative and positive rates of axillary MRI after NAC to asses lymph node response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Axillary lymph node metastasis proven by cytology * Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis) * Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria * Neoadjuvant chemotherapy Exclusion Criteria: * cN3 verified by imaging tests * N2 due to internal mammary involvement (N2b). * Tumors whose surrogate molecular subtype is luminal A. * Patients undergoing neoadjuvant endocrine therapy * Patients with local recurrences and metastatic tumors.
References
Publications (0)
Data not yet available
No reference posted for this study.